Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

By Swaisland H.  

Clinical Pharmacokinetics, Vol. 40, Iss. 4, 2001-01 ,pp. : 297-306

Adis International

Access to resources Recommend Favorite

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 10, 2012-10 ,pp. : 1233-1249

Informa Healthcare

Access to resources Recommend Favorite

Preservation of Bioavailability of Ingredients and Lack of Drug-Drug Interactions in a Novel Five-Ingredient Polypill (Polycap™): A Five-Arm Phase I Crossover Trial in Healthy Volunteers

By Patel Anil   Shah Tarang   Shah Gaurang   Jha Vijay   Ghosh Chinmoy   Desai Jagruti   Khamar Bakulesh   Chakraborty Bhaswat S.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 2, 2010-04 ,pp. : 95-103

Adis International

Access to resources Recommend Favorite

Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 3, 2015-03 ,pp. : 193-202

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

By Bence Aimee K.   Anderson Eric B.   Halepota Maqbool A.   Doukas Michael A.   DeSimone Phillip A.   Davis George A.   Smith Deborah A.   Koch Kevin M.   Stead Andrew G.   Mangum Steve   Bowen Carolyn J.   Spector Neil L.   Hsieh Showchien   Adams Val R.  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 39-49

Springer Publishing Company

Access to resources Recommend Favorite